Sustainment of N95 Respirator Manufacturing Capacity

N95 respirators are critical for frontline workers involved in biomanufacturing, pharmaceutical production, as well as delivery of healthcare, providing a crucial barrier against airborne pathogens and reducing the risk of infection and preventing contamination during manufacturing. The COVID-19 pandemic revealed vulnerabilities in the global supply chain of these items and specifically highlighted the lack of domestic manufacturing capacity necessary to support pandemic surge demands.

This effort seeks to sustain N95 Respirator manufacturing capacity through reserving capacity for a period of 36 months to maintain a minimum viable production capacity (determined to be no more than 10 percent of full capacity). Additionally, through this effort, the awardee(s) will develop and implement a long-term sustainment strategy for N95 respirator domestic manufacturing to maintain operational status of the domestic manufacturing capacity to be prepared for a future Public Health Emergency (PHE). Strategic oversight for the Project Agreement(s) supported by this RPP will be provided by BARDA.